Photocure’s Hexvix Gains Approval in China

Photocure ASA (PHCUF) has released an update.

Photocure ASA’s partner, Asieris Pharmaceuticals, has received marketing authorization for Hexvix in China, a drug used for enhanced detection of bladder cancer during cystoscopy. This approval marks a significant step for Photocure in expanding its presence in the Asian market, potentially impacting the company’s growth and stock value positively.

For further insights into PHCUF stock, check out TipRanks’ Stock Analysis page.